Peptic Ulcer Drugs Market Future Business Opportunities 2021-2028 | Daewoong Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., Pfizer Inc., Abbott Laboratories

Global Peptic Ulcer Drugs Market

Overview

PUD or peptic ulcer disease is caused by the bacteria Helicobacter pylori. Ulcers can also be caused by an imbalance of intestinal fluids in the stomach and duodenum. Bloating, heartburn, fatigue, and nausea are some of the signs of PUD. PUD may also cause weight loss, blood vomiting, and extreme pain in the mid or upper abdomen in severe cases.

By the end of 2027, the worldwide peptic ulcer drugs market is expected to be worth US$ 45,951.2 million.

Drivers

Over the forecast period, the global peptic ulcer drugs market is expected to rise due to an increasing preference for peptic ulcer drugs over surgical approaches for the treatment of PUD. This is due to the complexities of surgical treatment and peptic ulcer post-surgical complications.

To Request for Sample Report at – https://www.coherentmarketinsights.com/insight/request-sample/3246

Opportunities

Players in the global peptic ulcer drugs market should foresee attractive growth prospects in the developing healthcare sector in emerging markets. The healthcare sector in India is projected to cross US$ 372 billion by 2022, according to the India Brand Equity Foundation, owing to rising health consciousness, disposable income, and access to health insurance.

Restraints

Antibiotic resistance among helicobacter pylori strains is expected to stifle growth of the global peptic ulcer drugs market to some extent. Rising research and development activities on novel therapeutics for developing newer strains is expected to help the market expansion.

Key Takeaways

The Gastroesophageal Reflux Disease segment of the global peptic ulcer drugs market was worth US$ 18,185.7 million in 2018, and is projected to develop at a CAGR of 2.9 percent to US$ 23,492.2 million by 2027. The incidence and prevalence of gastroesophageal reflux disease in developed economies are due to the segment's development.

In terms of sales, the hospital pharmacies segment dominated the global peptic ulcer drugs market in 2018, contributing about 48.1 percent of the market, followed by retail pharmacies and drug stores. During the forecast period, the segment's development is expected to be aided by an increasing preference for peptic ulcer medications over surgical methods.

For More Information or Query or Customization before Buying, Visit at – https://www.coherentmarketinsights.com/insight/talk-to-analyst/3246

Market Trends
In patients with cardiovascular and inflammatory disorders, long-term aspirin use can increase the risk of gastrointestinal bleeding. As a result of this situation, proton pump inhibitors are now prescribed alongside aspirin.
Furthermore, due to their pharmacodynamic properties, H2 antagonists are becoming more popular in North America. Due to their rapid onset of action and long-lasting anti-secretory activity, H2 blockers are successful in the treatment of PUD.

Competitive Landscape

Key companies contributing in the global peptic ulcer drugs market are RedHill Biopharma, Novitium Pharma LLC, Takeda Pharmaceutical Co., Ltd., Abbott Laboratories, Eisai Co. Ltd., Daewoong Pharmaceutical Co., Ltd., GlaxoSmithKline plc., Yuhan Corporation, AstraZeneca plc., Pfizer Inc., Boehringer Ingelheim GmbH, and Cadila Healthcare Ltd.

Key Developments

Meridian Bioscience, Inc. sent Curian and the Curian HpSA assay to the US FDA for approval in November 2019. Using fluorescent lateral flow technology, the platform and assay was developed to directly identify Helicobacter pylori antigens in human stool.

Sihuan Pharmaceutical Holdings Group Ltd. reported in April 2019 that patient recruitment for its proprietary novel digestive system medication, Anaprazole Sodium, for a Phase II clinical trial in China has been completed early.

To Direct Purchase this Premium Research Report – https://www.coherentmarketinsights.com/insight/buy-now/3246

Contact:

Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837

About Us:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients to achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having an office at global financial capital in the U.S. and sales consultants in the United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies to not-for-profit organizations, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.

This release was published on openPR.